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Therapeutic drug monitoringAbstract Background: Tuberculosis/Human Immunodeficiency Virus (TB/HIV) is a very common
co-infection which carries a high mortality rate. Though World Health Organization recommends
co-treatment of TB/HIV to improve its outcome, Rifampicin potentially induces metabolism and
sub-therapeutic antiretroviral plasma levels of non nucleoside reverse transcriptase inhibitors and
protease inhibitors which may cause inadequate virological suppression if corrections are not timely
done. In Tanzania Therapeutic drug monitoring is not done; so the proportion of sub-therapeutic
ARV plasma levels among TB/HIV patients co-treated with anti-tuberculous drugs is not known.
The aim of this study was therefore to determine the magnitude and risk factors of sub-therapeutic
ARV plasma levels among adult HIV patients co-treated with anti tuberculous Medications.
Materials and methods: A cross sectional hospital based study was conducted among adult HIV
patients on ARV and TB co-treatment for at least one month. Patients were serially enrolled through
routine HIV care and treatment services until the sample size was reached. The information about
demographic, clinical and adherence level, Anti-TB duration, viral load, baseline and enrollment
CD4 counts, Hepatitis B co-infection and ARV plasma levels was collected and analyzed using
STATA 12 software.issio.de
burg.de
zania: A
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cross sectional clinic based study, Alex J MeResults: In total 118 patients were included in this study; of whom 26 (22%) had sub-therapeutic
ARV plasma levels. The sub-therapeutic ARV levels were independently associated with adherence
<95% (OR= 6.8, p= 0.001), female gender (OR = 3.4, p= 0.028) and virological failure
(OR= 3.8, p= 0.016). NVP based regimen was associated with sub-therapeutic drug levels on uni-
variate model (OR = 2.1, p= 0.010).
Conclusion: The magnitude of sub-therapeutic ARV plasma levels is high among adult HIV/TB co-
infected patients on anti-TB co-treatment in Tanzania. These patients stand a high risk of inadequate
virological suppression with a potential resistance development and a long term poor clinical out-
come. Identifying at risk patients and adherence enhancement could potentially improve the overall
outcome of this subgroup of patients in resource restricted setting like ours where TDM is not avail-
able.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis/Human immunodeficiency virus (TB/HIV)
co-infection has been a common phenomenon for decades,
causing a substantially high morbidity and mortality with
Tuberculosis ranking as the most common opportunistic infec-
tion and the most common cause of mortality among people
living with HIV/AIDS (PLWHA) especially in resource
restricted countries.1,2 In the year 2013 alone about 1.1 million
new cases of TB were reported in HIV positive patients glob-
ally where Majority of them (up to 78%) occurred in Africa.3
Tuberculosis occurs as the first manifestation of HIV/AIDS in
more than 50% of HIV positive patients 4 and deaths that are
linked to TB are significantly high especially in sub-Saharan
Africa where in some countries this rate is reported to be in
excess of 50%.5
Early initiation of Antiretroviral therapy (ART) in the
course of TB treatment has been shown to have a mortality
benefit 6,7 and WHO strongly recommends on co-treatment
of HIV/TB co-infection,8 with a rapid scaling up of Antiretro-
viral therapy programs especially in resource restricted coun-
tries, where tuberculosis is for the most part the widespread
opportunistic disease.9,10 In these areas thus ART is regularly
initiated when patients are being treated for tuberculosis,11,12
with a goal line being to provide an effective and safe
Antiretroviral therapy and anti-tuberculosis management
which is efficient enough to cure and prevent recurrence and
resistance.2,13
Despite this overall success, HIV and TB co-treatment faces
a number of important challenges including induction of sub-
therapeutic levels of both Non Nucleotide Reverse Transcrip-
tase Inhibitors (NNRTIs) and Protease Inhibitors (PIs).
Rifampicin which is the most important component of anti
tuberculous medications is remarkable for its induction effect
on CYT P450 iso-enzymes which may adversely increase the
metabolism and disposition of both NNRTIs and PIs which
can potentially cause inadequate plasma levels of these drugs
and severely limiting the treatment options for optimal Highly
Active Antiretroviral Therapy (HAART) regimens 14–19 espe-
cially in resource limited settings. Whereas it has been estab-
lished from prior studies that Rifampicin may be a cause of
significant suboptimal levels of both NNRTIs and PIs,20,21
sub-therapeutic ARV plasma levels as a consequence
have been demonstrated to be associated with inadequate
virological suppression which may subsequently lead intoet al. Sub therapeutic drug levels among
d (2016), http://dx.doi.org/10.1016/j.ajmselection of resistant strains and a long term inadequate
immune recovery and overall poor clinical outcome.22,23
In developed countries this challenge is overcome using
therapeutic drug monitoring (TDM) that is readily available
for routine practical use where the patients’ NNRTIs and
PIs plasma levels are monitored for any adverse drug levels,
and corrections of dosages are timely done to improve the
therapeutic outcomes.24,25 TDM has been usefulness in a num-
ber of clinical settings including monitoring of ARV plasma
levels in TB/HIV co-treatment. In this regard a better treat-
ment outcome has been documented among patients whose
treatment was TDM guided than those whose ARV plasma
levels were not monitored.25,26 Even though TDM is not done
in most of the resource limited countries, the available studies
from these settings demonstrate that a significant proportion
of HIV patients co-treated with anti Tuberculous drugs
(Rifampicin) have sub-therapeutic NNRTIs and PIs plasma
levels and some of the locations have reported even higher
rates of sub-therapeutic ARV (NNRTIs and PIs) plasma levels
than most of resource rich countries.21,27–29
In Tanzania no study has ever reported ARV plasma
levels in HIV positive patients who are co-treated with
Rifampicin. The current study was therefore designed to
determine the magnitude and the associated risk factors of
sub-therapeutic NNRTIs (Efavirenz and Nevirapine) and
PIs (Lopinavir) plasma levels among adult HIV positive
patients who were co-treated with anti-TB in northwestern
Tanzania. The results from this study will be useful to assist
the overall optimization of management of patients on
ARV/anti-TB co-treatment especially in resource limited
settings. Also the results from this study will provide a base
for further studies on the subject and add to the existing
body of knowledge regarding ARV plasma levels especially
in resource limited countries.
2. Materials and methods
2.1. Study design and setting
This was a cross-sectional hospital based study which was
done between April 2012 and July 2013 at Bugando Medical
Centre (BMC) at Care and Treatment Center (CTC) in Mwan-
za, Tanzania. BMC is a tertiary and teaching hospital for the
North Western part of Tanzania. It has a capacity of 1000
beds, and it serves around 13 million people. At Bugando,HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A
e.2016.10.001
Sub therapeutic drug levels among HIV/TB co-infected patients 3CTC services started a way back 2004, and are routinely done
as part and parcel of outpatient activities. Currently the center
serves a total of more than 10,000 patients, whereby more than
4000 of them are active on ART. Tuberculosis screening is rou-
tinely done on daily bases and as of now about 300 patients are
on TB/HIV co-treatment.
2.2. Study population
This study involved adult HIV and TB co-infected patients
diagnosed to have either Pulmonary TB (smear positive and
smear negative) or Extra Pulmonary Tuberculosis (EPTB)
according to WHO TB diagnosis guideline 2010 30 and put
on anti-TB Treatment. The HIV diagnosis was as per
WHO guidelines and all patients were treated with standard
dose of Nevirapine 200 mg twice daily or Efavirenz 600 mg
once daily or Lopinavir/r 400/100 mg twice daily and Rifam-
picin 600 mg or 450 mg once daily for patients weighing more
than 45 kg and less than 45 kg respectively. All patients aging
over 18 years and co-treated with ARV and anti-tuberculosis
medications for at least one month were included in this
study.
2.3. Sample size, patients’ enrollment and data collection
A minimum sample of 100 patients was estimated from cross
sectional studies’ formula by Leslie Kish, assuming 30% of
adult HIV positive patients co-treated with Rifampicin had
subtherapeutic ARV levels 21,28 at an allowable error of 0.09.
After a written informed consent a structured questionnaire
was used to collect information about demographic data, body
mass index (BMI), date of HIV diagnosis, date of ART initia-
tion, the ART regime, ART adherence level, baseline CD4 and
on study CD4 count, Hepatitis B status, type of tuberculosis,
time on anti tuberculous medication, viral load and plasma
NNRTIs and PIs levels.
The ART adherence level in the last 30 days was assessed
using pill counts.31 The pill counts were performed by the
study pharmacist, who counted the number of remaining pills
at each drug refill visit. Pill count-based adherence was
assessed using the formula [Adherence = (Number of pills dis-
pensed -Number of pills returned 100)/(Number of pills pre-
scribed daily  Number of days between pharmacy visits)].
Adequate adherence level was defined as a value P95% pills
whereas poor adherence was defined as a value 695%. The
patients were instructed to take their medication at night as
prescribed and come the following morning for blood sample
collection before their next ART dose. Two blood samples
were drawn, one for viral load which was done at BMC main
laboratory and the other sample was sent to Germany for
TDM to determine the plasma concentrations of Efavirenz,
Nevirapine and Lopinavir.
2.4. Sample collection, processing and analysis
For each patient, 5 ml of whole blood was collected in plasma
EDTA bottles for TDM, approximately 8–12 h after the last
dose of antiviral drugs and just before the next dose was done.
The samples were immediately centrifuged at 3000 rpm for
3 min to obtain plasma that was transferred into cryovials.
The cryovials were stored at 20 C before shipment. ThePlease cite this article in press as: Gunda DW et al. Sub therapeutic drug levels among
cross sectional clinic based study, Alex J Med (2016), http://dx.doi.org/10.1016/j.ajmsamples were packed and shipped to Germany in cold boxes
with cooling packs maintaining a temperature of 30 C.
The plasma concentrations of NVP, EFV, and LPV were
determined by a sensitive validated simultaneous assay using
reverse-phase (Zorbax XD8-CI8; Agilent Technology) high
performance liquid chromatography (HP 1100; Agilent Tech-
nology), coupled with tandem mass spectrometry (MS-MS)
(API 2000; Applied Biosystems) as described previously.32
An additional 5 ml of whole blood was collected in a tube sup-
plemented with EDTA (BD Biosciences) for plasma prepara-
tion and sent to BMC main laboratory for viral load
analysis using COBAS AmpliPrep/COBAS TaqMan (Roche
Molecular Systems, USA) according to manufacturer’s guide-
lines as described previously.33
2.5. Data management and analysis
Data were managed using Epi Data 3.1 (CDC Atlanta, USA)
and analysis was done using STATA version 12 (College Sta-
tion, Texas, USA). ARV drug concentrations were recorded as
continuous variables. The therapeutic ranges in ng/ml were
defined as 1000–4000 for EFV, and 3400–8000 and 3000–
7000 for NVP and LPV respectively; thus three categories of
ARV plasma drug concentrations were defined as used in other
studies,24 and any levels below the lower limit of the respective
drug were coded as being sub-therapeutic ARV level for that
drug and drug levels that were within therapeutic range were
coded as therapeutic ARV levels, while those that were above
the upper limit of therapeutic range were coded as supra-
therapeutic ARV levels. Categorical variables were summa-
rized as proportion and the significance of the difference in dis-
tribution within the categories of ARV plasma drug
concentrations was assessed using Pearson’s Chi-square test
or Fisher’s exact test where appropriate. We used probability
plots and Shapiro-Wilk normality test to assess the normality
of continuous variables. Parametric continuous data were
summarized as mean with standard deviation and the signifi-
cance of difference in means within categories of ARV plasma
drug concentrations was assessed using Student’s t-test. Non-
parametric continuous data were summarized as median with
interquartile range and the difference in medians within the
categories of ARV plasma drug concentrations was compared
using Wilcoxon rank-sum test. The odds ratios (ORs) and 95%
confidence intervals (CIs) of risk factors associated with sub-
therapeutic ARV plasma levels were calculated using univari-
ate logistic regression model followed by multivariate logistic
regression model. All factors associated with sub-therapeutic
ARV plasma levels in the univariate model with p-values less
than 0.05 were considered for inclusion in the multivariate
model. A stepwise approach was used to derive a Parsimonious
model, and all associated factors in the final model were con-
sidered significant if the P-value was less than 0.05.
3. Ethical consideration
The permission to conduct this study and publish the results
was found from The Catholic University of Health and Allied
Sciences and Bugando Medical Centre (CUHAS/BMC) joint
ethics review board. Written consent was obtained from all
study participants. Patients’ identifiers were not included to
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Table 1 The baseline demographic, clinical and laboratory
characteristics of 118 adult HIV Positive patients attending
CTC at Bugando with ARV and anti-TB Co-treatment.
Factor Number (%) or median [IQR]
Gender
Female 69 (58.5)
Males 49 (41.5)
Age (years) 38 [32–43]
Geographical location
Urban 52 (44.1)
Rural 66 (55.9)
WHO stage
Stage 3 75 (63.6)
Stage 4 43 (36.4)
BMI index(kg/M2)
Under weight 22 (18.6)
Normal weight 79 (67.0)
Overweight 10 (8.5)
Obese 07 (5.9)
Hepatitis B
Positive 09 (07.6)
Negative 109 (92.4)
ARV regimes
EFV based 104 (88.1)
LPV based 10 (08.5)
NVP based 4 (03.4)
Subtherapeutic ARV 26 [22.0]
Subtherapeutic regimen
EFV 19 (18.3)
LPV 4 (40.0)
NVP# 3 (75.0)
Duration on ART (months) 10 [3–22]
Adherence level
>95% 92 (79.6)
<95% 24 (20.4)
Duration on anti-TB (months) 5 [2–6]
TB category
PTB Sputum Positive 71 (60.2)
PTB Sputum Negative 24 (20.3)
EPTB 23 (19.5)
*ART: antiretroviral therapy, CD4: cluster of differentiation 4,
CTC: Care and Treatment center; EFV: Efavirenz, EPTB: extra
pulmonary TB, LPV: Lopinavir, NVP: Nevirapine, PTB: Pul-
monary Tuberculosis.
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4.1. Baseline demographic, clinical and laboratory
characteristics of 118 adult HIV positive patients cotreated with
tuberculosis drugs at Bugando CTC
A total of 118 patients were included in this study, where more
than 58% of these patients were females with a median age of
38 32–43 years. The median time on anti-TB was 5 2–6 months,
and on ARV 10 3–22 months with an adherence rate of >95%
in more than 79% of the studied patients (Table 1). The most
common regimen used was TDF+ FTC+ EFV 80 (67.8%),
followed by AZT + 3TC+ EFV 24 (20.3%) which shows
that most patients 104 (88%) were on EFV based regimen as
summarized in Fig. 1.
4.2. Subtherapeutic ARV plasma levels and associated factors
among 118 adult HIV positive patients co-treated with anti-
tuberculosis drugs
In total 26 (22%) of the studied patients had sub-therapeutic
ARV plasma levels (Table 1), and by regimen 19 (28.3%), 57
(54.8%), and 28 (26.9%) of those who were on EFV based reg-
imen had sub-therapeutic, therapeutic and supra-therapeutic
EFV plasma levels respectively, whereas 4 (40%), 5 (50%),
and 10 (10%) had sub-therapeutic, therapeutic and supra-
therapeutic LPV plasma levels respectively. Furthermore
Sub-therapeutic and therapeutic NVP plasma levels were
found in 3 (75%) and 1 (25%) respectively and there was no
study participant who had supra-therapeutic NVP plasma
levels (Fig. 2). Fig. 3 summarizes the distribution of variables
by plasma ARV levels. Several factors were tested for associa-
tion with sub-therapeutic ARV plasma levels. On a univariate
model the sub-therapeutic ARV plasma levels were strongly
associated with a female gender (OR = 2.9, p= 0.031), adher-
ence level of less than 95% (OR= 4.5, p< 0.002), virological
failure (OR = 2.9, p= 0.027), and NVP based regimen
(OR= 2.1, p= 0.010), whereas on a multivariate model only
Female gender (OR = 3.4, p= 0.028) and adherence <95%
(OR= 6.8, p= 0.001) remained independently associated
with sub-therapeutic ARV plasma levels. Moreover the
patients with sub-therapeutic ARV plasma levels were conse-
quently more likely to have virological failure (OR = 3.8,
p= 0.016) (Table 2). However there was no significant statis-
tical association found between sub-therapeutic ARV plasma
levels and age, geographical location, BMI, WHO clinical
stage, CD4 levels, Hepatitis B co-infection, time on ART, time
on anti-TB, and viral load of more than 400 copies/ll and TB
category.5. Discussion
The objective of this study was to determine the proportion
and risk factors of sub-therapeutic ARV plasma levels among
adult HIV positive patients co-treated with anti-TB. In this
study, 26 (22%) of the patients co-treated with anti-TB had
subtherapeutic ARV plasma levels, and by regimen 19/104
(18.3%) had subtherapeutic EFV levels, while 3/4 (75%) and
4/10 (40%) had subtherapeutic NVP and LPV levels respec-
tively. The sub-therapeutic ARV plasma levels were indepen-Please cite this article in press as: Gunda DW et al. Sub therapeutic drug levels among
cross sectional clinic based study, Alex J Med (2016), http://dx.doi.org/10.1016/j.ajmdently associated with female gender and adherence level of
less than 95% on a multivariate analysis; otherwise, NVP
based regimen was only strongly in association with sub-
therapeutic ARV plasma levels on univariate model alone.
Comparable ranges of sub-therapeutic ARV levels have
been reported in different studies across the world assessing
plasma concentration of NNRTIs or PIs. In previous studies
sub-therapeutic EFV plasma levels were reported with a preva-
lence varying between 20% and 32%. For example in London
Sathia et al. reported EFV sub-therapeutic plasma levels in
20% of patients who were co-treated with Rifampicin,21 while
in Kenya 34 this was reported in 32% of patients who were co-
treated with Rifampicin. The magnitude of sub-therapeuticHIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A
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Figure 1 The combined Anti retroviral therapy regimens. *ABC: Abacavir; AZT: Zidovudine; d4T: Stavudine; ddI: Didanosine; EFV:
Efavirenz; FTC: Emtricitabine; LPV: Lopinavir; NPV: Nevirapine, r: ritonavir; TDF: Tenofovir; 3TC: Lamivudine.
Figure 2 Distribution of ARV plasma levels as sub-therapeutic, Therapeutic or supra-therapeutic among 118 adult HIV patients
cotreated with TB drugs. *ARV: Antiretroviral; EFV: Efavirenz; HIV: Human immunodeficiency virus; LPV: Lopinavir; NVP:
Nevirapine; TB: Tuberculosis.
Sub therapeutic drug levels among HIV/TB co-infected patients 5EFV levels reported from Kenya is comparatively higher than
our finding, probably because this study was done among
patients with a number of other co-morbidities requiring sev-
eral other co-medications which could have considerably con-
tributed to this higher report of sub-therapeutic Efavirenz
plasma levels.
Sub-therapeutic NVP level is also reported in a range of 34–
39% among patients co-treated with Rifampicin in various
other studies. In Kenya 34.5% of patients studied for clinically
significant drug interaction had sub-therapeutic NVP.34 In
studies from UK 21 and South Africa,28 the sub-therapeutic
NVP plasma levels were reported in 36% and 39% of patients
co-treated with Rifampicin respectively. These rates are on the
other hand lower than our findings, but of note all these stud-
ies suggest that TB/HIV co-treated patients on NVP-based
regimen were the most likely to have subtherapeutic ARV drugPlease cite this article in press as: Gunda DW et al. Sub therapeutic drug levels among
cross sectional clinic based study, Alex J Med (2016), http://dx.doi.org/10.1016/j.ajmlevels, as compared to EFV based regimen even though the
number of patients who were on NVP based regimen in our
study was much smaller.
Rifampicin is remarkable for its CYP45O induction effect,
which subsequently increases the metabolism of NNRTIs and
PIs.17,35,36 This phenomenon affects NVP more extensively
than EFV, and it is essentially because of the differences in bio-
transformation pathways which are largely influenced by
CYP2B6 and NAT2 genetic polymorphism.37–39 Nevirapine
metabolism occurs through a number of CYP450 isoenzymes
inclusive of CYP2B6, CYP3A and CYP2C which are Rifampi-
cin ‘‘inducible”,40 an event that has also been suggested to
affect the PIs substantially.10,36,41 As a consequence this
increases the clearance of NVP and PIs among those individu-
als who are co-treated with Rifampicin containing tuberculosis
drugs. A number of studies have demonstrated the conse-HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A
e.2016.10.001
Figure 3 Distribution of variables by plasma ARV drug levels as sub-therapeutic or therapeutic. *AD< 95%: Adherence level of less
than 95%; AD> 95%: Adherence level of more than 95%; ARV: Antiretroviral; HepB pos: Hepatitis B positive; HepB neg: Hepatitis B
positive; VF: virological failure; WHO: world health organization; WHO 3: WHO clinical stage 3; WHO 4: WHO clinical stage 4.
6 D.W. Gunda et al.quence of this interaction between NVP and Rifampicin
including a recent study from Mozambique which indicated
that NVP plasma concentrations were much lower while on
anti tuberculosis drugs than after discontinuation of tuberculo-
sis drugs42 with a large proportion of NVP concentration being
below therapeutic range for the period of cotreatment with
tuberculosis drugs than thereafter.
Even though protease inhibitors including Lopinavir have a
short half life requiring multiple dosages a day, LPV is still the
most preferred PI when used in its co formulated form with
ritonavir as a pharmacological booster (LPV400 mg/
r100 mg), since it is well tolerated and has a better virological
efficacy43,44 as compared to other PIs. However at this strength
of LPV/r co formulation Rifampicin significantly increases the
clearance of both drugs leading into failure of virological con-
trol. Based on this a number of studies have demonstrated a
better virological control with super boosted LPV/r including
combined strengths of 400/400 mg or 800/200 mg regi-
mens,45,46 however with increased risk of toxicity which could
negatively affect the patients’ adherence to medications.
On the contrary Efavirenz is mainly metabolized by
CYP2B6.47,48 Though this enzyme can also be induced by
Rifampicin it has been shown that Isoniazid is one of impor-
tant components of the TB fixed dose combination, inhibits
CYP2B6 especially among individuals who are slow metaboliz-
ers (with CYP2B6 loss of function), and decreases the EFV
clearance with attendant increase in plasma EFV concentra-
tion.49,50 This phenomenon is reportedly more frequent among
African than European descendants,51 and it has been
observed in about 40% of African individuals in some study
settings.52 Among patients who were on TB treatment in
Mozambique their plasma EFV concentrations were higher
with anti tuberculosis than after discontinuation of anti tuber-
culosis drugs.42 In this study it was further shown that only a
small proportion of patients had sub-therapeutic EFV plasma
levels (9%) as compared to more than 37% who had supra-
therapeutic levels of EFV while on anti tuberculosis.
These observations are similar to our findings that of the
104 patients who were on EFV based regimen, 28 (26.9%)Please cite this article in press as: Gunda DW et al. Sub therapeutic drug levels among
cross sectional clinic based study, Alex J Med (2016), http://dx.doi.org/10.1016/j.ajmhad supra-therapeutic (>4000 ng/mL) EFV plasma concentra-
tions (Fig. 2) whereas only 1 (10%) participant on LPV and
none of those who were on NVP based regimen had supra-
therapeutic plasma levels. These findings suggest that patient
on HIV/TB co-treatment should as well be monitored for
potential ART drug toxicities.
One aim of this study was to determine the factors that will
give clinical prediction of subtherapeutic ARV levels in adult
patients who are co-treated with anti-TB. These factors which
have also been reported by other studies, include adherence of
<95%,53,54 NVP based regime55 and female gender.34,53 In the
face of this association our results suggest that the occurrence
of any of these risk factors independently augments the likeli-
hood of sub-therapeutic ARV levels plasma among patients
co-treated with Rifampicin.
Many of the findings of this study were consistent with pre-
vious studies and logical but one surprising finding is that of
the female gender being a predictor of sub-therapeutic plasma
ARV levels among adult HIV patients co-treated with anti-TB.
The female gender is documented as one of the inter-individual
differences which have been shown to alter the apparent oral
clearance of ARVs.56 This may be one of the explanations that
the female sex stands as one of the predictors of sub-
therapeutic ARV levels among patients co-treated with anti-
TB. Additional factors which may alter oral clearance of
ARV are inclusive of geographical location and Hepatitis B
Virus (HBV) co-infection.56,57 However in our study these
two additional factors did not show any significant statistical
association to sub-therapeutic ARV levels.
Apart from the fact that both NNRTIs and PIs undergo
their disposition through CYP450 iso enzymes,10 on the other
hand the plasma levels of these drugs are determined by
adherence levels to medications especially among patients on
EFV based regimens.42 Prior studies had indicated that the
sub-therapeutic EFV plasma levels on TB co-treatment are less
frequent and are more common among those patients with
inadequate adherence level.42 Since isoniazid reduces clearance
of EFV, improvement of adherence to ART medications may
positively alter the plasma levels of EFV and possibly giveHIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A
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Table 2 Univariate and multivariate analysis for factors associated with sub-therapeutic ARV plasma levels among 118 adult HIV
positive patients on TB co-treatment at Bugando.
Variables Sub-therapeutic ARV levels Unadjusted Adjusted
Yes (n) = 26 No (n) = 82 OR (95% CI) p-Val OR (95% CI) p-Val
Gender
Male 06 (12.2) 43 (87.8)
Female 20 (29.0) 49 (71.0) 2.9 (1.1–7.9) 0.031 3.5 (1.1–10.6) 0.028
Age in years 33 [27–44] 38 [32–43] 1.0 (0.9–1.1) 0.513
Geog location
Urban 10 (19.2) 42 (80.8)
Rural 16 (24.2) 50 (75.8) 0.7 (0.3–1.8) 0.515
BMI index
Under WT 04 (18.2) 18 (81.8)
Normal WT 19 (24.1) 60 (75.9)
Over WT 03 (17.7) 14 (82.3) 1.0 (0.9–1.1) 0.842
WHO stage
Stage 3 16 (21.3) 59 (78.7)
Stage 4 10 (23.3) 33 (76.7) 1.1(0.5–2.7) 0.808
Initial CD4
<200 cells/ll 18 (22.8) 61 (77.2)
>200 cells/ll 08 (20.5) 31 (79.5) 0.9 (0.3–2.2) 0.779
Enroll CD4
<200 cells/ll 09 (20.0) 36 (80.0)
>200 cells/ll 17 (23.3) 56 (76.7) 1.2 (0.5–3.0) 0.676
HBV co-infection
Yes 03 (33.3) 06 (66.7)
No 23 (21.1) 86 (78.9) 0.4 (0.0–3.5) 0.424
Adherence
>95% 15 (16.0) 79 (84.0)
<95% 11 (45.8) 13 (54.2) 4.5 (1.7–11.8) 0.002 6.8 (2.2–20) 0.001
ART months 9.5 [2–20] 11 [3–22] 1.1 (0.9–1.4) 0.999
VL (copies/ll)
>400 11 (23.9) 35 (76.1)
<400 15 (20.8) 57 (79.2) 1.2(0.5–2.9) 0.694
VF (VLP 104/ll)
Yes 09 (39.1) 14 (60.9)
No 17 (17.9) 78 (82.1) 2.9(1.1–7.9) 0.027 3.8 (1.2–11.4) 0.016
Anti-TB months 5 [3–6] 4.5 [2–6] 1.1(0.9–1.4) 0.261
TB category
PTB SP 14 (19.7) 57 (80.2)
PTB SN 09 (37.5) 15 (62.5)
EPTB 03 (13.0) 20 (87.0) 1.0(0.6–1.7) 0.112
ARV regimen
EFV 19 (18.3) 85 (81.7)
LPV 04 (40.0) 06 (60.0)
NVP# 03 (75.0) 01 (25.0) 2.1(1.2–2.8) 0.010 - -
*ART: antiretroviral therapy, CD4: cluster of differentiation 4, CI: confidence interval, EFV: Efavirenz, EPTB: extra pulmonary TB, Geog:
Geographical, HBV: Hepatitis B, IQR: Interquartile range, LPV: Lopinavir, NVP: Nevirapine, PTB: Pulmonary Tuberculosis, SN: Smear
Negative, SP: Smear positive, VF: Virological failure, VL: viral load.
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NVP and Lopinavir based regimens.
Therapeutic drug levels are a key to successful ART,57,58
and any low drug levels observed in patients on ART have
been extrapolative of a failure to achieve an immediate
virological containment and a longer term immunologicalPlease cite this article in press as: Gunda DW et al. Sub therapeutic drug levels among
cross sectional clinic based study, Alex J Med (2016), http://dx.doi.org/10.1016/j.ajmfailure.53,59 Findings of sub-therapeutic drug levels among
patients co-treated with anti-TB in the current study are
accompanied by a co-occurrence of both high levels of virolog-
ical failure and substantially low CD4 counts on enrollment as
a consequent. In this study virological failure was found in
39.1% of the patients with sub-therapeutic ARV levels andHIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A
e.2016.10.001
8 D.W. Gunda et al.on enrollment CD4 count of <200 cells/ll was found in more
than one-third, 9/26 (34.6%) of these patients with sub-
therapeutic NNRTIs and PIs plasma levels.
On clinical grounds these findings suggest that these
patients stand a high risk of a subsequent potential of develop-
ing and accumulating resistant viral strains,23,60,61 when these
drug levels are not corrected quickly. However this is a great
challenge in Tanzania and other resource limited settings
where TDM is not done. Our findings that female gender, poor
adherence, and certain regimens are predictive of sub-
therapeutic drug levels are helpful to clinicians in these settings
who need to maintain a high index of suspicion for sub-
therapeutic drug levels in such patients and to counsel patients
on the importance of adherence. This study had a number of
limitations including a small sample size especially of patients
on NVP and LPV based regimen. Also this being a cross sec-
tional and a single clinic based study, the results from this
study may not necessarily be generalizable to the general pop-
ulation; therefore, a longitudinal study with a larger sample
size is recommended.
6. Conclusion
The magnitude of sub-therapeutic ARV plasma levels is sig-
nificantly high among adult HIV positive patients on ARV
and anti-TB co-treatment attending HIV care and treatment
centers in Tanzania. These patients are at a high risk of
immediate inadequate virological suppression with a poten-
tial resistance development and a long term poor clinical out-
come. Since TDM is not available in most resource limited
settings to assist in identifying these patients early and mak-
ing timely correction to improve their overall outcome on
ARVS, Clinician in resource limited settings such as Tanza-
nia should maintain a high index of suspicion and identify
potential patients for a closer clinical follow-up and adher-
ence augmentation.
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